Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

About this update from Helix Biopharma Corp.

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy (TheNewswire)   Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce the following appointments, effective immediately: Zachary T. Stadnyk, former TSX Life Sciences Lead and a biotech capital markets executive, has been appointed to the Company’s Board of Directors (the “Board”), and Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary of the Company.   Mr. Stadnyk brings more than 15 years of experience across biotechnology, capital markets, and public company leadership, including serving as Head of Life Sciences at the TSX and TSXV, where he advised biotech issuers, boards and institutional investors on public listings, capital formation and strategic positioning, with deep experience in public market execution. Over the course of his career, he has led and supported over $100 million in institutional financings, contributed to strategic transactions including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth, and advised public companies across the biotech, healthcare and AI sectors.   Ms. Butterworth is a seasoned corporate governance professional with over 15 years of experience supporting public and private companies in governance and regulatory compliance across multiple jurisdictions, spanning the pharmaceutical, technology, and finance sectors. Based in British Columbia, both appointees strengthen Helix’s Canadian capital markets and governance expertise as the Company advances its capital markets strategy, including preparations for a planned Nasdaq listing through the Multijurisdictional Disclosure System (“MJDS”).   “As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority,” said Thomas Mehrling, MD, PhD, Chief Execu...

View stock analysis, news, and events for Helix Biopharma Corp.